Literature DB >> 16475944

Heparan sulphate proteoglycans and viral vectors : ally or foe?

Romain R Vivès1, Hugues Lortat-Jacob, Pascal Fender.   

Abstract

The attachment of viruses to the host cell surface is a critical stage that will largely condition cell permissivity and productive infection. The understanding of such mechanisms is therefore essential for gene therapy applications involving viruses, as this step will influence both targeting and delivery efficiency of the gene of interest. Viral attachment depends upon the recognition and binding of viral envelope/capsid proteins to specific cellular receptors that can be from very diverse origins. Amongst them are heparan sulphate proteoglycans (HSPGs), a family of glycoproteins which, through the large binding properties of their heparan sulphate (HS) polysaccharide chains, serve as attachment receptor for a great number of viruses. The aim of this review is to provide an update on the multiple roles of HSPGs during viral infection, with a special focus on viruses used as gene delivery vectors. Consequences of HS binding for gene therapy applications will be assessed, as well as the various strategies that have been developed to potentiate the advantages or to overcome the drawbacks resulting from viral vector interaction with HS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16475944     DOI: 10.2174/156652306775515565

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  19 in total

Review 1.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

Review 2.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

Review 3.  Multiple roles of the coagulation protease cascade during virus infection.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

4.  Syndecans in skeletal muscle development, regeneration and homeostasis.

Authors:  Addolorata Pisconti; Jennifer D Bernet; Bradley B Olwin
Journal:  Muscles Ligaments Tendons J       Date:  2012-06-17

5.  The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site.

Authors:  Elodie Crublet; Jean-Pierre Andrieu; Romain R Vivès; Hugues Lortat-Jacob
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

6.  Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.

Authors:  Nundehui Díaz-Lezama; Zhijian Wu; Elva Adán-Castro; Edith Arnold; Miguel Vázquez-Membrillo; David Arredondo-Zamarripa; Maria G Ledesma-Colunga; Bibiana Moreno-Carranza; Gonzalo Martinez de la Escalera; Peter Colosi; Carmen Clapp
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

7.  Heparin/heparan sulfate N-sulfamidase from Flavobacterium heparinum: structural and biochemical investigation of catalytic nitrogen-sulfur bond cleavage.

Authors:  James R Myette; Venkataramanan Soundararajan; Jonathan Behr; Zachary Shriver; Rahul Raman; Ram Sasisekharan
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

8.  Heparin/heparan sulfate 6-O-sulfatase from Flavobacterium heparinum: integrated structural and biochemical investigation of enzyme active site and substrate specificity.

Authors:  James R Myette; Venkataramanan Soundararajan; Zachary Shriver; Rahul Raman; Ram Sasisekharan
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  A novel function of heparan sulfate in the regulation of cell-cell fusion.

Authors:  Christopher D O'Donnell; Deepak Shukla
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

10.  Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo.

Authors:  Michael A van Geer; Conny T Bakker; Naoya Koizumi; Hiroyuki Mizuguchi; John G Wesseling; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.